Last Updated : January 3, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Biliary tract carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0344-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC), in combination with chemotherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC), in combination with chemotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 26-Oct-23 |
|---|---|
| Call for patient/clinician input closed | 15-Dec-23 |
| Clarification: - Patient input submission received from CCRAN collectively with CCSN & GI Society | |
| Submission received | 07-Dec-23 |
| Submission accepted | 21-Dec-23 |
| Review initiated | 22-Dec-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 18-Mar-24 |
| Deadline for sponsors comments | 27-Mar-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 25-Apr-24 |
| Expert committee meeting (initial) | 08-May-24 |
| Draft recommendation issued to sponsor | May 21, 2024 To May 23, 2024 |
| Draft recommendation posted for stakeholder feedback | 30-May-24 |
| End of feedback period | 13-Jun-24 |
Last Updated : January 3, 2024